HanAll Biopharma Launches Phase III Double-Blind, Placebo-Controlled VELOS-4 Study to Assess Tanfanercept in Treating Dry Eye Syndrome.

TAR-200 treatment alone achieves over 80% total remission in high-risk patients with non-muscle-invasive bladder cancer.

Guangzhou Bio-gene Technologies has launched the first phase of clinical trials for its CAR-T cell therapy BG1805, which targets CLL-1.

selectION, Inc. has shared encouraging outcomes from its initial human Phase 1b study concerning its primary drug, si-544, targeted at individuals with atopic dermatitis.

AriBio Granted EMA Approval for Phase 3 Trials of AR1001 in Alzheimer’s Treatment (POLARIS-AD).

Ractigen Therapeutics has received FDA clearance for RAG-01, a pioneering saRNA treatment for NMIBC that does not respond to BCG.

U.S. FDA Sanctions Single-Dose Gene Treatment BEQVEZ™ (fidanacogene elaparvovec-dzkt) by Pfizer for Adult Hemophilia B Patients.

Advanced gastrointestinal cancer patients continue to test dosages with the novel T-cell engager, CDH17 X CD3 cabotamig (ARB202).

Cidara Therapeutics regains worldwide control for developing and marketing CD388, also launches a $240 million private funding initiative.

FDA has prioritized GSK’s submission to broaden the use of Jemperli (dostarlimab) with chemotherapy for treating all adult patients with initial advanced or relapsed endometrial cancer.

Alkermes plc has launched the Vibrance-1 study, a phase 2 clinical trial aimed at assessing the safety and effectiveness of ALKS 2680 versus a placebo in individuals diagnosed with type 1 narcolepsy.

Atom Bioscience focused on innovative therapies for metabolic and inflammatory conditions, has initiated patient enrollment across the United States for a Phase 2b/3 study of ABP-671.